Acertannin Prevented Dextran Sulfate Sodium-induced Colitis by Inhibiting the Colonic Expression of IL-23 and TNF-α in C57BL/6J Mice

Abstract

The present study investigates the effects of acertannin on colitis induced by dextran sulfate sodium (DSS) and changes in the colonic levels of the cytokines interleukin (IL)-1β, IL-6, IL-10, IL-23, tumor necrosis factor (TNF)-α, the chemokine monocyte chemoattractant protein (MCP)-1, and vascular endothelial growth factor (VEGF).

We examine the following: inflammatory colitis was induced in mice by 2% DSS drinking water given ad libitum for 7 days. Red blood cell, platelets, and leukocyte counts and hematocrit (Ht), hemoglobin (Hb), and colonic cytokine and chemokine levels were measured. The disease activity index (DAI) was lower in DSS-treated mice orally administered acertannin (30 and 100 mg/kg) than in DSS-treated mice. Acertannin (100 mg/kg) inhibited reductions in the red blood cell count and Hb and Ht levels in DSS-treated mice. Acertannin prevented DDS-induced mucosal membrane ulceration of the colon and significantly inhibited the increased colonic levels of IL-23 and TNF-α. Our findings suggest that acertannin has potential as a treatment for inflammatory bowel disease (IBD).

Key words

Acer saccharum - Aceraceae - acertannin - inflammatory bowel disease - interleukin-23 - tumor necrosis factor-α

^* The late Honorary Professor

Publication History

Received: 20 October 2022

Accepted after revision: 16 February 2023

Accepted Manuscript online:
16 February 2023

Article published online:
15 March 2023

• References

• 1 Apostolidis E, Li L, Lee C, Seeram NP. In vitro evaluation of phenolic-enriched maple syrup extracts for inhibition of carbohydrate hydrolyzing enzymes relevant to type 2 diabetes management. J Function Food 2011; 3: 100-106
• 2 Sato K, Nagai N, Yamamoto T, Mitamura K, Taga A. Identification of a novel oligosaccharide in maple syrup as potential alternative saccharide for diabetes mellitus patients. Int J Mol Sci 2019; 20: 5041
• 3 Ma H, Liu W, Frost L, Kirschenbaum LJ, Dain JA, Seeram NP. Glucitol-core containing gallotanins inhibit the formation of advanced glycation end-products mediated by their antioxidant potential. Food & Function 2016; 7: 2213-2222
• 4 Liu W, Wei Z, Ma H, Cai A, Liu Y, Sun J, DaSilva NA, Jonson SL, Kirschenbaum LJ, Cho BP, Dain JA, Rowley DC, Shaikh ZA, Seeram NP. Anti-glycation and anti-oxidative effects of a phenolic-enriched maple syrup extract and its protective effects on normal human colon cells. Food Funct 2017; 8: 757-766
• 5 Park KH, Yoon KH, Yin J, Le TT, Ahn HS, Yoon SH, Lee MW. Antioxidative and anti-inflammatory activities of galloyl derivatives and antidiabetic activities of Acer ginnala . Evid Based Complement Alternat Med 2017; 2017: 6945912
• 6 Sheng J, Liu C, Petrova S, Wan Y, Chen HD, Seeram NP, Ma H. Phenolic-enriched maple syrup extract protects human keratinocytes against hydrogen peroxide and methylglyoxal induced cytotoxicity. Dermatol Ther 2020; 33: e13426
• 7 González-Sarrías A, Li L, Seeram NP. Effects of maple (Acer) plant part extracts on proliferation, apoptosis and cell cycle arrest of human tumorigenic and non-tumorigenic colon cells. Phyother Res 2012; 26: 995-1002
• 8 González-Sarrías A, Ma H, Edmonds ME, Seeram NP. Maple polyphenols, ginnalins A–C, induce S- and G2/M-cell cycle arrest in colon and breast cancer cells mediated by decreasing cyclins A and D1 levels. Food Chem 2013; 136: 636-642
• 9 Bi W, Gao Y, Shen J, He C, Liu H, Peng Y, Zhang C, Xiao P. Traditional uses, phytochemistry, and pharmacology of the genus Acer (maple): A review. J Ethnopharmacol 2016; 189: 31-60
• 10 Bi W, He CN, Li XX, Zhou LY, Liu RJ, Zhang S, Li GQ, Chen ZC, Zhang PF. Ginnalin A from Kujin tea (Acer tataricum subsp. Ginnala) exhibits a colorectal cancer chemoprevention effect via activation of the Nrf2/HO-1 signaling pathway. Food Funct 2018; 9: 2809-2819
• 11 Menu I, Molagoda N, Arachchilage W, Karunarathne WAHM, Lee MH, Kang CH, Lee KT, Choi YH, Lee S, Kim GY. Acertannin attenuates LPS-induced inflammation by interrupting the binding of LPS to the TLR4/MD2 complex and activating Nrf2-mediated HO-1 activation. Int Immunopharmcol 2020; 113: 109344
• 12 Japan Intractable Diseases Information Center. Japan Intractable Diseases Information Center Report. Inflammatory bowel disease (IBD) (Designated intractable disease No. 97). Tokyo, Japan: Public Interest Incorporated Foundation, Intractable Disease Medical Research Foundation; 2022
• 13 Berre CL, Roda G, Protic MN, Danese S, Peyrin-Biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opin Biol Ther 2020; 20: 363-378
• 14 Chen W, Xiang L, Li L. Therapeutic efficacy of the combination therapy of corticosteroids and 5-aminosalicylic acid for treatment of Pyoderma Gangrenosum with ulcerative colitis. Indian J Dermatol 2020; 65: 38-41
• 15 Damião AOMC, de Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World J Gastroenterool 2019; 25: 1142-1157
• 16 Khare V, Kmjic A, Frick A, Gmainer C, Asboth M, Jimenez K, Lang M, Baumgartner M, Evstatiev R, Gasche C. Mesalamine and azathiopurine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation. Sci Rep 2019; 9: 2842
• 17 Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifeitz AS. Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 2019; 10
• 18 Kimura Y. Preventive effects of Mallotus japonica cortex extract on dextran sulfate sodium-induced ulcerative colitis in C57BL/6J mice. Nat Prod J 2020; 10: 177-185
• 19 Kimura Y, Baba K. Xanthoangelol isolated from Angelica keiskei roots prevents dextran sulfate sodium-treated colitis in mice. Nat Prod J 2020; 10: 655-663
• 20 Hatano T, Hattori S, Ikeda Y, Shingu T, Okuda T. Gallotannins having a 1, 5-Anhydro-D-glucitol core and some ellagitannins from Acer species. Chem Pharm Bull 1990; 38: 1902-1905
• 21 Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96: 795-803
• 22 GBD 2017 Inflammatory Bowel Disease Collaborators (Maelekzadeh R, Naghavi M: These authors jointly supervised the study). The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020; 5: 17-30
• 23 Magro F, Cordeiro G, Dias AM, Estevinho MM. Inflammatory bowel disease – non-biological treatment. Pharmacol Res 2020; 160: 105075
• 24 Shen W, Durum SK. Synergy of IL-23 and Th17 cytokines: New light on inflammatory bowel disease. Neurochem Res 2010; 35: 940-946
• 25 Bunte K, Beikler T. Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodonititis and immune-mediated inflammatory diseases. Int J Mol Sci 2019; 20: 3394
• 26 Moschen A, Tilg H, Raine T. IL-12, IL-23and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol 2019; 16: 185-196
• 27 Neurath M. IL-23 in inflammatory bowel diseases and colon cancer. Cytokine Growth Factor Rev 2019; 45: 1-8
• 28 Jefremow A, Neurath M. All are equal, some are more equal: targeting IL-12 and 23 in IBD – A clinical perspective. Immunotargets Ther 2020; 9: 289-297
• 29 Almradi A, Hanzel J, Sedano R, Parker CE, Feagan BG, Ma C, Jairath V. Clinical trials of IL-12/IL-23 inhibitors in inflammatory bowel disease. BioDrugs 2020; 34: 713-721
• 30 Atri C, Guerfali FZ, Laouini D. Role of human macrophage polarization in inflammation during infectious diseases. Int J Mol Sci 2018; 19: 18011
• 31 Fine S, Papamichael K, Cheifetz AS. Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol 2019; 15: 656-664
• 32 Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA. Novel p19 protein engages IL-12p40 to form a cytokine, Il-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725
• 33 Dennehy K, Willment JA, Williams DL, Brown GD. Reciprocal regulation of IL-23 and IL-12 following co-activation of Dectin-1 and TLR signaling. Eur J Immunol 2009; 39: 1379-1386
• 34 Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 2005; 22: 285-294
• 35 Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000; 51: 289-298
• 36 Hayden MS, Ghosh S. Regulation of NF-κB by TNF family cytokines. Semin Immunol 2014; 26: 253-266
• 37 Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, OʼFarrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Waal Malefyt R, Moore KW. A receptor for heterodimeric cytokine IL-23 is composed of IL-12R β1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168: 5699-5708
• 38 McDonald BD, Dyer EC, Rubin DT. IL-23 monoclonal antibodies for IBD: So many, So different?. J Crohns Colitis 2022; 16: ii42-ii53
• 39 Parigi TL, Iacucci M, Ghosh S. Blockade of IL-23: What is in the pipeline?. J Crohns Colitis 2022; 16: ii64-ii72
• 40 Kasier GC, Yan F, Polk DB. Mesalamin blocks tumor necrosis factor growth inhibition and nuclear factor κB activation in mouse colonocytes. Gastroenterol 1999; 116: 602-609